Neurim Pharmaceuticals
CompanyIsrael
Neurim Pharmaceuticals develops one asset, approved (melatonin in autism spectrum disorder). Mostly small molecule acting on Oxidative stress and ROS signalling, inflammation and MTNR1B; based in Israel.
- Assets
- 1
- Furthest
- Approved
- Trials
- 8
- Signals
- 0
Pipeline
1Melatonin receptor agonist that regulates circadian rhythm and sleep-wake cycles.
ApprovedSmall moleculeOxidative stress and ROS signallingInflammationautism spectrum disorderautistic disorder
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms4
- Trials9
- Similar companies6
Updated 7 Oct 2026 · 28 sources